Peptides for Energy
The peptides people most often research for energy, with how much evidence exists for each. A long list does not mean any of them is proven to work in people.
- Peptides listed
- 6
- With human trials
- 1
- FDA approved (any use)
- 0
- MOTS-cMitochondrial-derived peptideHuman RCT evidence, 4 of 4Scientific reports 2021, PMID 34413391Human6Animal5Summarised3PCAC voted 7–5 for 503A (Jul 2026)For energyOverview
- SermorelinGHRH analogNo study with an outcome for energyPubMed search, 11 Oct 2026Human0Animal0Summarised0Compounded by prescriptionFor energyOverview
- CJC-1295GHRH analogNo study with an outcome for energyPubMed search, 11 Oct 2026Human0Animal0Summarised0Not FDA approved · research chemicalFor energyOverview
- CJC-1295 + IpamorelinGHRH + GHRP blendNo study with an outcome for energyPubMed search, 11 Oct 2026Human0Animal0Summarised0Not FDA approved · research blendOverview
- BPC-157Gastric pentadecapeptideNo study with an outcome for energyPubMed search, 11 Oct 2026Human2Animal0Summarised0PCAC voted 8–6 for 503A (Jul 2026)Overview
- IpamorelinGHRP (ghrelin receptor agonist)No study with an outcome for energyPubMed search, 11 Oct 2026Human0Animal0Summarised0Not FDA approved · research chemicalOverview
What this list does not show
Search demand tells you what people are curious about, not what works. Read each peptide's evidence before anything else.
Search interest is not evidence
This list follows what people search for and discuss. It says nothing about how well any peptide works.Animal results may not carry over
Doses, routes and effects seen in rodents or cell dishes often have no tested human equivalent.Approval covers specific uses
An FDA approval applies to the conditions and doses on the label, not to every goal a drug is searched with.Combinations are a separate question
Blends and stacks put several peptides together. Evidence for one peptide is not evidence for the mix.Energy and fatigue as a medical question
MedlinePlus defines fatigue as a feeling of weariness, tiredness, or lack of energy, and says it can be a normal response to activity, stress, boredom or lack of sleep.[21]
The same page advises contacting a provider if tiredness lasts for weeks.[21]
Energy findings come from mice and from a mitochondrial drug
MOTS-c has 6 human-only and 5 animal papers on the energy topic, BPC-157 has 2 human-only papers, and sermorelin, CJC-1295 and ipamorelin have none.
Calculated from source our PubMed count ledger ledger (PubMed title/abstract counts, 2026-10-02); mots-c human only 6, animal only 5, rct 2; sermorelin human only 0, animal only 0, rct 0; cjc-1295 human only 0, animal only 0, rct 0; bpc-157 human only 2, animal only 0, rct 0; ipamorelin human only 0, animal only 0, rct 0. Formula: Counts copied from each peptide ledger: humanOnly = human studies not also tagged animal, animalOnly = animal studies not tagged human, rct = human randomised trials. They count papers mentioning the topic, not positive results.
SLU-PP-332 raised energy expenditure and fatty acid oxidation in mice; "energy" here means metabolic rate, not a person feeling less tired.[22]
MOTS-c improved physical performance in young, middle-age and old mice.[23]
SS-31 (elamipretide) was tested for fatigue in people with primary mitochondrial myopathy, and the larger trial missed its primary endpoints for walk distance and fatigue score.[24]
A smaller crossover trial of the same drug reported less fatigue and fewer muscle complaints on the symptom scale.[25]
Common questions
What are the best peptides for energy?
Human fatigue data exist only for SS-31 in a rare mitochondrial disease; the other energy results are in mice.[24]
Do peptide injections give energy?
No cached trial in healthy or tired adults shows that; the energy-expenditure data are from mice.[22]
Is there a peptide stack for energy?
None has human data in the files; sermorelin, CJC-1295 and ipamorelin have zero papers on this topic in the ledger.[23]
When should low energy be checked by a doctor?
MedlinePlus says to contact a provider if tiredness lasts for weeks.[21]
Explore nearby goals
Sources
- 1Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors.Scientific reports · 2021PMID 34413391Accessed 2 Oct 2026
- 2PubMed search: (sermorelin[tiab] OR Geref[tiab]) (34 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 3PubMed search: (sermorelin[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab] OR "GHRH 1-29"[tiab]) AND (elderly[tiab] OR aging[tiab] OR "older adults"[tiab] OR adults[tiab]) AND (treatment[tiab] OR therapy[tiab] OR administration[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 4PubMed search: (sermorelin[tiab] OR Geref[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 5PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) (33 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 6PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 7PubMed search (Ipamorelin): ipamorelin[tiab] (50 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search (Ipamorelin): ipamorelin[tiab] AND (half-life[tiab] OR pharmacokinetic*[tiab]) (4 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: "BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab] (230 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11PubMed search: "BPC-157"[tiab] AND humans[mh] (52 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 12PubMed search: ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND (patients[tiab] OR clinical trial[pt] OR randomized[tiab]) (25 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 13PubMed search: ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND (colitis[tiab] OR inflammatory bowel[tiab]) (48 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 14PubMed search: ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND (tendon[tiab] OR ligament[tiab] OR muscle[tiab] OR bone[tiab] OR arthritis[tiab]) (58 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15PubMed search: ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND (nerve[tiab] OR neuropath*[tiab] OR spinal[tiab] OR liver[tiab] OR wound[tiab] OR burn[tiab]) (90 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 16PubMed search: (sermorelin[tiab] OR Geref[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (21 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 17PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 18PubMed search (Ipamorelin): ipamorelin[tiab] AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 19PubMed search: ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (57 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 20PubMed search: ("BPC-157"[tiab] OR "BPC 157"[tiab]) AND (human[tiab] OR patient*[tiab] OR volunteer*[tiab]) AND (adverse[tiab] OR safety[tiab] OR "side effects"[tiab]) (19 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 21Official web pageOfficial web page · web page
- 22A Synthetic ERR Agonist Alleviates Metabolic Syndrome.The Journal of pharmacology and experimental therapeutics · 2024PMID 37739806Accessed 2 Oct 2026
- 23MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.Nature communications · 2021PMID 33473109Accessed 2 Oct 2026
- 24Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.Neurology · 2023PMID 37268435Accessed 2 Oct 2026
- 25A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy.Journal of cachexia, sarcopenia and muscle · 2020PMID 32096613Accessed 2 Oct 2026
Found an error? Report a correction.